The observed lack of monotherapy impact of p110β inhibition is supported by other studies, indicating that BRAFV600E PTEN melanoma is refractory to p110β monotherapy blockade, with combined inhibition of p110α, p110γ, and p110δ required to arrest its proliferation. The gene discussed is PIK3CD; the disease is melanoma.